pyrroles and sr141716
pyrroles has been researched along with sr141716 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z | 1 |
| Barth, F; Boulu, L; Congy, C; Fabre, G; Finance, O; Hortala, L; Rinaldi-Carmona, M; Sadoun, F | 1 |
| Astarita, G; DiPatrizio, NV; Li, X; Piomelli, D; Schwartz, G | 1 |
Other Studies
3 other study(ies) available for pyrroles and sr141716
| Article | Year |
|---|---|
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain | 2007 |
Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif.
Topics: Administration, Oral; Animals; Brain; Drug Design; Gastrointestinal Transit; Piperidines; Pyrazoles; Pyrroles; Rats; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Endocannabinoid signal in the gut controls dietary fat intake.
Topics: Amidohydrolases; Animals; Benzyl Compounds; Brain; Cannabinoid Receptor Modulators; Dietary Fats; Eating; Endocannabinoids; Gastrointestinal Tract; Intestine, Small; Lipids; Male; Phospholipase D; Piperidines; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Vagotomy | 2011 |